1859 Strengthens Leadership with Appointment of Consulting CSO and Strategic Pharma Advisors, Bringing Deep Oncology and Immunology Expertise
"We are proud to welcome Jeff, Venkat and Michael to 1859 during this pivotal time for the company," said 1859 CEO, Sanket Agrawal.
- "We are proud to welcome Jeff, Venkat and Michael to 1859 during this pivotal time for the company," said 1859 CEO, Sanket Agrawal.
- "With their therapeutic expertise in oncology and immunology, and track record in creating and leading biotech companies to clinical assets, we are poised to continue pushing our strategic vision forward."
- Continuing into 2024, 1859 will amplify and diversify its internal pipeline into high-value oncology, and immunology and inflammation therapeutic areas.
- Venkat Reddy, Ph.D., Chief Scientific Officer at General Inception, brings deep expertise and a wealth of experience in oncology and autoimmune therapeutic areas.